Cross-resistance between rifampicin and rifabutin and its relationship with rpoB gene mutations in clinically isolated MDR-TB atrains

Tuberculosis and Respiratory Diseases

Volumn 60, Issue 2, 2006, Pages 171-179

  Kim, Byoung Ju ^a,b,c   Oh, Seung Hwan ^a,b   Cho, Eun Jin ^b   Park, Seung Kyu ^a,b  

^a National Masan TB Hospital   (South Korea)

^b International Tuberculosis Research Center   (South Korea)

^c Masan National Hospital   (South Korea)

Author keywords

Cross resistance; MDR TB; Rifabutin; Rifampin; rpoB mutation

Indexed keywords

RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CODON; CROSS RESISTANCE; GENE MUTATION; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OLIGONUCLEOTIDE PROBE; WILD TYPE;

EID: 33646587671     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2006.60.2.171     Document Type: Article

References (19)

1. Woodley CL, Kilburn JO. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin. Am Rev Respir Dis 1982;126:586-7.
2. O'Brien RJ, Lyle MA, Snider DE Jr. Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial disease. Rev Infect Dis 1987;9:519-30.s
3. O'Brien RJ, Geiter LJ, Lyle MA. Rifabutin (ansamycin LM 427) for the treatment of pulmonary Mycobacterium avium complex. Am Rev Respir Dis 1990;141:821-6.
4. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148:1541-6.
5. Chien HP, Yu MC, Ong TF, Lin TP, Luh KT. In vitro activity of rifabutin and rifampin against clinical is olates of Mycobacterium tuberculosis in Taiwan. J Formos Med Assoc 2000;99:408-11.
6. Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002;6:164-5.
7. Saribas Z, Kocagoz T, Alp A, Gunalp A. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates. J Clin Microbiol 2003;41:816-8.
8. Senol G, Erbaycu A, Ozsoz A. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother 2005;17:380-4.
9. Shim TS, Kim JS, Park MS, Lim CM, Lee SD, Koh YS, et al. Rifabutin suceptibility and rpoB gene mutations in multi-drug resistant Mycobacterium tuberculosis. Tuberc Respir Dis 2000;48:853-69.
10. Lew WJ, Park YK, Kim BJ, Chang CH, Bai GH, Kim SK. The proportion of rifabutin-susceptible strains among rifampicin-resistant isolates and its specific rpoB mutations. Tuberc Respir Dis 2005;59:257-65.
11. Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998;42;621-8.
12. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangaharam PRJ, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:1853-7.
13. Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infection 2004;10:662-5.
14. Telenti A. Genetics of drug resistance in tuberculosis. Clin Chest Med 1997;18:55-64.
15. de Beenhouwer H, Lhiang Z, Jannes G, Mijs W, Machtelinchx L, Rossau R, et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tubercle Lung Dis 1995;76:425-30.
16. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993;37:2054-8.
17. Canetti G, Fox W, Khomenko A, Mahler H, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969;41:21-43.
18. Bai GH. Anti-tuberculosis drug resistance in Korea. CDMR 2005;16:101-7.
19. NCCLS. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; Approved standard.